Novel Immunotherapy OST-HER2 Shows Promise for Osteosarcoma Treatment, Featured in PBS Documentary
OS Therapies' investigational immunotherapy OST-HER2 demonstrates statistically significant benefit in Phase 2b clinical trials for recurrent osteosarcoma, with FDA submission planned for 2025.
OST-HER2 Shows Promise in Preventing Recurrence of Lung Metastatic Osteosarcoma
OST-HER2 demonstrated a statistically significant 12-month event-free survival (EFS) rate of 33.3% compared to 20% in historical controls for recurrent, fully resected osteosarcoma with lung metastases.
OS Therapies Advances OST-HER2 Towards FDA Submission with Manufacturing Agreements
OS Therapies has initiated commercial manufacturing for OST-HER2, an immunotherapy targeting HER2, in preparation for a BLA submission to the FDA.
OS Therapies Secures $6 Million Private Placement to Advance OST-HER2
OS Therapies has announced a $6 million private placement to fund the clinical and regulatory milestones for OST-HER2, its lead therapeutic candidate.
OS Therapies Anticipates Topline Data for OST-HER2 Osteosarcoma Trial
OS Therapies expects to release topline data from its Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma in December 2024.
OS Therapies' OST-HER2 Shows Promise in Osteosarcoma Phase 2b Trial
OS Therapies' Phase 2b trial of OST-HER2 met its primary endpoint, demonstrating a statistically significant improvement in 12-month Event Free Survival in recurrent osteosarcoma patients.
OS Therapies Completes Phase 2b Trial of OST-HER2 in Osteosarcoma, Topline Data Expected in December
OS Therapies has completed dosing in its Phase 2b clinical trial of OST-HER2 for recurrent osteosarcoma, with topline data anticipated in December 2024.